SC 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)

SC 13D - Ensysce Biosciences, Inc. (0001716947) (Subject)

SC 13G/A - Leisure Acquisition Corp. (0001716947) (Subject)

SC 13G/A - Leisure Acquisition Corp. (0001716947) (Subject)

SC 13G - Leisure Acquisition Corp. (0001716947) (Subject)

SC 13G - Leisure Acquisition Corp. (0001716947) (Subject)

HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- MRC Global Inc. (NYSE:MRC) ("MRC Global" or the "Company"), the leading global distributor of pipe, valves and fittings (PVF) and other infrastructure products and services to diversified gas utility, energy and industrial end-markets, today announced that Daniel Silvers has been appointed to the Company's Board of Directors, effective immediately. Mr. Silvers will serve on the Board's Compensation and Environmental, Social, Governance and Enterprise Risk Committees. Mr. Silvers' appointment is made in conjunction with a cooperation agreement that the Company has reached with Engine Capital, L.P. ("Engine"). Robert Wood, MRC Global'

Believes it is Critical to Add Directors with an Investor Mindset, and Capital Allocation and Financial Markets Experience Underscores Engine's Repeated Attempts to Avoid an Election Contest, Including by its Willingness to Settle for Reduced Board Representation Engine Capital, L.P. (together with its affiliates, "Engine"), a significant shareholder of MRC Global Inc. (NYSE:MRC) ("MRC" or the "Company") and the owner of nearly 4.3% of the Company's outstanding common stock, today announced it has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with its nomination of two highly qualified candidates for election to the Company's Board of

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (OTC:LACQ, LACQW))) today announced that, in connection with the closing of its previously announced merger with Leisure Acquisition Corp. ("LACQ"), the combined company, Ensysce Biosciences, Inc., will commence trading its common stock and warrants under the ticker symbols "LACQ" and "LACQW," respectively, on the OTC Market on July 1, 2021. As previously announced, the merger was approved by LACQ's shareholders on June 28, 2021 and closed on June 30, 2021. The Company will announce further trading information at a later time. Forward Looking Statements This press release contains certain

NEW YORK, June 1, 2021 /PRNewswire/ -- Leisure Acquisition Corp. ("LACQ" or the "Company") (NASDAQ:LACQ, LACQU, LACQW))), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that on June 1, 2021, Nasdaq notified LACQ that trading in the Company's securities on Nasdaq will be suspended effective with the open of the market on Thursday, June 3, 2021 due to the Company's failure to complete an initial business combination by June 1, 2021, which date the notice stated represented the full extent of the Nasdaq Hearing Panel's discretion in this matter. The Company expects that its securities will be immed

NEW YORK and SAN DIEGO, May 07, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce"), which has entered into an agreement for a business combination with Leisure Acquisition Corp. ("LACQ") (NASDAQ:LACQ, LACQU, LACQW))), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that Ensysce's subsidiary, Covistat, will be presenting at the upcoming American Thoracic Society (ATS) Annual Meeting to be held May 14-19, 2021. ATS 2021 showcases the latest advances and discoveries in respiratory science, patient care and global respiratory health. Covistat will present a summary of its findings th

NEW YORK and SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce") and Leisure Acquisition Corp. ("LACQ") (NASDAQ:LACQ, LACQU, LACQW))), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that Ensysce has received U.S. Food and Drug Administration ("FDA") allowance for an Investigational New Drug (IND) application for PF614-MPAR™, a two-step extended-release oxycodone prodrug which is designed to provide abuse deterrent and overdose protection properties. PF614-MPAR™ is designed as an extended-release oxycodone prodrug with both trypsin-activated abuse protection (TA

GAINESVILLE, Ga., April 15, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of additional agreements with an existing customer, Ensysce Biosciences, Inc. ("Ensysce"). Under these new agreements, Recro will provide early-stage development and manufacturing services to support two of Ensysce's development programs. Recro and Ensysce have already commenced the initial phase of these projects. "We are delighted that Ensysce has elected to expand our relationshi

NEW YORK and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Ensysce Biosciences Inc. ("Ensysce"), a clinical stage pharmaceutical company developing medicines for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, and Leisure Acquisition Corp. (NASDAQ: LACQ) ("LACQ") today announced the appointment of David Humphrey to Ensysce's management team as its Chief Financial Officer. Mr. Humphrey brings over 20 years of experience with development-stage companies as they progress toward product commercialization. Prior to joining Ensysce, Mr. Humphrey was Chief Financial Officer of Senomyx, Inc., a publicly-held biotechnology company which he led through an acquisition by F

NEW YORK and SAN DIEGO, Feb. 2, 2021 /PRNewswire/ -- Leisure Acquisition Corp. (NASDAQ: LACQ, LACQU, LACQW) ("Leisure"), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, and Ensysce Biosciences, Inc. (together with its affiliated entities, "Ensysce" or the "Company"), jointly announced today that Leisure and Ensysce will host an investor conference call on February 3, 2021 to discuss their previously announced business combination (the "Transaction") whereby Ensysce will merge into a wholly-owned subsidiary of Leisure in a transaction that reflects a pro forma enterprise valuation for Ensysce of approximately

NEW YORK and SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Leisure Acquisition Corp. ("Leisure") (NASDAQ: LACQ, LACQU, LACQW), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, announced today that it has entered into a definitive agreement to acquire Ensysce Biosciences, Inc. (together with its affiliated entities, "Ensysce" or the "Company").  The transaction reflects an enterprise valuation for Ensysce of $207 million, including the Company's existing convertible indebtedness, but excluding transaction expenses as well as the impact of Leisure's sponsor shares and subject to certain closing adjustments.     Consid